Details
Industries BiotechnologyPharmaceuticalPrecision MedicineHeadquarters Regions Western US Founded Date 1991 Founders Kevin Kimberlin, Mark Skolnick, Peter D. Meldrum, Walter Gilbert Operating Status Active Last Funding Type Post-IPO Debt Also Known As Myriad Pharmaceuticals Legal Name Myriad Genetics, Inc.
Stock Symbol NASDAQ:MYGN Company Type For Profit
Number of Exits
Contact Email cscomments@myriad.com Phone Number (800) 469-7423
Myriad Genetics personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.
Myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.